Where does OncoArendi Therapeutics S.A. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), OncoArendi Therapeutics S.A. ranks #27,038 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does OncoArendi Therapeutics S.A. hold?

OncoArendi Therapeutics S.A. holds 10 US utility patents granted between 2016 and 2024, spanning 9 technology areas.

What is OncoArendi Therapeutics S.A.'s Innovation Score?

OncoArendi Therapeutics S.A. has an Innovation Score of 34.3 out of 100 (47th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does OncoArendi Therapeutics S.A. focus on?

OncoArendi Therapeutics S.A.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 10 patents, ranking #1,884 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is OncoArendi Therapeutics S.A.'s patent grant rate increasing or decreasing?

OncoArendi Therapeutics S.A.'s recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for OncoArendi Therapeutics S.A.'s patents?

OncoArendi Therapeutics S.A.'s patents average 23.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the OncoArendi Therapeutics S.A. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

OncoArendi Therapeutics S.A.

USPTO PatentsView assignee record - 10 granted patents across 9 technology areas, recorded in grant years 2016–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Oncoarendi ranks #27,038 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 9 technology areas.

#27,038
of 49,997 US assignees by volume: 47th percentile
by Innovation Score (34.3/100): 23.9
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R27038 · Foreign Corporation #27,038 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #27,038/49,997
PHOTO-FINISH Ohio Associated…
CPC-NARROW A61P · 9 areas
INNOV-THIN 34.3/100
CLAIMS-DENSE 23.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Ohio Associated Enterprises, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Oncoarendi’s 34.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (24%) Velocity 1.1 pts (3%) Breadth 10.6 pts (31%) Claim depth 14.3 pts (42%)

Qualcomm Incorporated · highest

85
OncoArendi Therapeut… · this assignee

34
3D Lighting… · lowest

7

What this shows Oncoarendi's Innovation Score is 34.3/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Oncoarendi?

Each dot is one of Oncoarendi’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Oncoarendi’s own 23.9 claims/patent is ABOVE the 14.5 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Oncoarendi vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Oncoarendi's grants concentrate

OncoArendi Therapeutics S.A. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2019 (3 grants) versus a trough of 1 in 2016. By volume, Oncoarendi sits between Ohio Associated Enterprises, LLC and Opla Energy Ltd..

Oncoarendi's three-year grant acceleration

OncoArendi Therapeutics S.A. shows 1 grants in 2022–2024 against only 6 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Ohio Associated E…

10
Oilquick Deutschl…

10
Oldcastle Archite…

10
Olive Seed Indust…

10
One Home Brands

10
One Lambda

10
One Star Internat…

10
Opla Energy

10
Oncoarendi Therap… ◀

10

What this shows OncoArendi holds 10 patents at rank #27,046, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near OncoArendi

By rank, the assignees closest to #27,046 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in OncoArendi's primary technology class.

Oncoarendi's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 47th percentile higher than 47% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

OncoArendi Therapeutics S.A. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	1	10.0%
2017	1	10.0%
2018	1	10.0%
2019	3	30.0%
2020	2	20.0%
2021	1	10.0%
2024	1	10.0%

Which technologies does OncoArendi Therapeutics S.A. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

C07D - Heterocyclic Compounds 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 5

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 2

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

C07K - Peptides 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

OncoArendi Therapeutics S.A.'s patent record in context - here's where to go next.

OncoArendi Therapeutics S.A.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #27,038 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare OncoArendi Therapeutics S.A. against Ohio Associated Enterprises, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.